Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Colorectal Neoplasms 9Rectal Neoplasms 4Lymphoma, B-Cell, Marginal Zone 4Surgical Wound Infection 3Pancreatic Neoplasms 3Lymphoma 2Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Prostatic Neoplasms 1Preventive Effect of Quintuple Therapy on Metachronous Liver Metastases in Patients With Colorectal Cancer 1Postoperative Complications 1Persistence of Infection With Helicobacter Pylori 1Neutropenia 1Neoplasms 1Mouth Neoplasms 1Metastatic Castration-Resistant Prostate Cancer (mCRPC) 1Lymphoma, Non-Hodgkin 1Leukemia, B-Cell 1Inflammatory Bowel Diseases 1Hematologic Neoplasms 1Head and Neck Neoplasms 1For Patients With Colorectal Cancer Liver Metastases Who Were Not Able to Curative Surgical Resection.Focused on the Treatment Effect With the Quintuple Method 1Febrile Neutropenia 1Familial primary gastric lymphoma 1Dysbiosis 1Diverticulitis 1Colonic Neoplasms 1Anastomotic Leak 1Adenocarcinoma 1

Interventions

enzalutamide 2sipuleucel-T 1Vancomycin 1Metronidazole 1Docetaxel 1Ciprofloxacin 1Amoxicillin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Metastatic Castration-Resistant Prostate Cancer (mCRPC) × Metronidazole × Clear all
NCT06126731 2025-11-24

Combination Study of Antibiotics With Enzalutamide (PROMIZE)

Institute of Cancer Research, United Kingdom

Phase 1/2 Recruiting
39 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡